Guardant Health’s Shield Blood Test Receives Strong FDA Committee Recommendation for Colorectal Cancer Screening
PALO ALTO, Calif. - In a groundbreaking development for cancer screening, Guardant Health, a leading precision oncology company, has announced that the Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration’s (FDA) Medical Devices Advisory Committee strongly recommends approval of the company’s Shield blood test for colorectal cancer (CRC) screening. This non-invasive screening option is specifically aimed at adults aged 45 and older who are at average risk for the disease.
The recommendation comes as a significant milestone for Guardant Health and emphasizes the potential of the Shield blood test in revolutionizing the early detection and diagnosis of colorectal cancer. With CRC being the second leading cause of cancer-related deaths in the United States, the approval of this primary non-invasive screening option could have far-reaching implications in saving lives and improving patient outcomes.
The Shield blood test utilizes advanced molecular and genetic analysis to identify specific DNA mutations and alterations associated with colorectal cancer. By analyzing circulating tumor DNA (ctDNA) in a simple blood sample, the test offers a painless and accessible alternative to traditional invasive screening methods such as colonoscopy and sigmoidoscopy.
The FDA committee’s strong recommendation for approval highlights the robustness and accuracy of the Shield blood test in detecting early-stage colorectal cancer. This breakthrough technology offers hope for a more efficient and patient-friendly approach to screening, which could lead to enhanced compliance rates and ultimately, a higher number of lives saved.
Furthermore, Guardant Health has previously asserted its commitment to delivering excellence in precision oncology. In line with this commitment, the company has announced inducement grants under Nasdaq Listing Rule 5635(c)(4). On April 22, 2024, the Compensation Committee of Guardant’s Board of Directors approved restricted stock units (RSUs) and non-qualified stock option awards for non-executive employees. With 215,601 shares of common stock granted as RSUs and an additional 98,076 shares available for purchase through stock options, the company is significantly bolstering its workforce and incentivizing talent within its precision oncology sector.
This dual announcement of the FDA committee’s recommendation and the inducement grants showcases Guardant Health’s dedication to advancing the field of precision oncology. As the company forges ahead with groundbreaking efforts in cancer screening and treatment, its innovative technologies and strategic decisions continue to position Guardant Health as a true leader in the fight against cancer.
Comments